Intervention not reported
All‐cause mortality at 31 to 100 days · Adults with haematological malignancies treated with intensive chemotherapy or radiotherapy, or both, with or without haematopoietic stem…
It is very uncertain whether the intervention changes all‐cause mortality at 31 to 100 days (very low certainty).
1 finding from 1 review
Intervention not reported
Number of participants with any bleeding ‐ not reported · Adults with haematological malignancies treated with intensive chemotherapy or radiotherapy, or both, with or without haematopoietic stem…
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Intervention not reported
Number of participants with clinically significant bleeding · Adults with haematological malignancies treated with intensive chemotherapy or radiotherapy, or both, with or without haematopoietic stem…
1 finding from 1 review
Intervention not reported
Serious infections ‐ not reported · Adults with haematological malignancies treated with intensive chemotherapy or radiotherapy, or both, with or without haematopoietic stem…
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Intervention not reported
Length of hospital admission ‐ not reported · Adults with haematological malignancies treated with intensive chemotherapy or radiotherapy, or both, with or without haematopoietic stem…
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Intervention not reported
Hospital readmission rate ‐ not reported · Adults with haematological malignancies treated with intensive chemotherapy or radiotherapy, or both, with or without haematopoietic stem…
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Intervention not reported
Quality of life (0 to 3 months) · Adults with haematological malignancies treated with intensive chemotherapy or radiotherapy, or both, with or without haematopoietic stem…
1 finding from 1 review
Intervention not reported
Number of participants with any bleeding (0 to 3 months) · Adults with haematological malignancies treated with intensive chemotherapy or radiotherapy, or both, with or without haematopoietic stem…
The intervention showed no clear difference in number of participants with any bleeding (0 to 3 months) (low certainty).
1 finding from 1 review
Intervention not reported
Number of participants with clinically significant bleeding (0 to 3 months) · Adults with haematological malignancies treated with intensive chemotherapy or radiotherapy, or both, with or without haematopoietic stem…
The intervention showed no clear difference in number of participants with clinically significant bleeding (0 to 3… (low certainty).
1 finding from 1 review
Intervention not reported
Serious infections (0 to 3 months) · Adults with haematological malignancies treated with intensive chemotherapy or radiotherapy, or both, with or without haematopoietic stem…
The intervention showed no clear difference in serious infections (0 to 3 months) (low certainty).
1 finding from 1 review
Intervention not reported
Length of hospital admission (days) (0 to 3 months) · Adults with haematological malignancies treated with intensive chemotherapy or radiotherapy, or both, with or without haematopoietic stem…
1 finding from 1 review
Intervention not reported
Hospital readmission (0 to 3 months) · Adults with haematological malignancies treated with intensive chemotherapy or radiotherapy, or both, with or without haematopoietic stem…
The intervention showed no clear difference in hospital readmission (0 to 3 months) (low certainty).
1 finding from 1 review
Intervention not reported
All‐cause mortality at 31 to 100 days · Adults with haematological malignancies treated with intensive chemotherapy or radiotherapy, or both, with or without haematopoietic stem…
1 finding from 1 review
Intervention not reported
Quality of life ‐ not reported · Adults with haematological malignancies treated with intensive chemotherapy or radiotherapy, or both, with or without haematopoietic stem…
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Overall survival · people with chronic lymphocytic leukaemia
Anti‐CD20 mAb maintenance therapy showed no clear difference in overall survival compared with observation (moderate certainty).
1 finding from 1 review
Grades 3 and 4 adverse events · people with chronic lymphocytic leukaemia
Immunomodulatory drug maintenance therapy may leads to higher grade 3/4 adverse events compared with placebo/observation (low certainty).
1 finding from 1 review
Progression‐free survival · people with chronic lymphocytic leukaemia
Immunomodulatory drug maintenance therapy probably leads to lower progression‐free survival compared with placebo/observation (moderate certainty).
1 finding from 1 review
Treatment‐related mortality · people with chronic lymphocytic leukaemia
Immunomodulatory drug maintenance therapy showed no clear difference in treatment‐related mortality compared with placebo/observation (low certainty).
1 finding from 1 review
Treatment discontinuation · people with chronic lymphocytic leukaemia
It is very uncertain whether immunomodulatory drug maintenance therapy changes treatment discontinuation compared with placebo/observation (very low certainty).
1 finding from 1 review
All adverse events · people with chronic lymphocytic leukaemia
Immunomodulatory drug maintenance therapy probably leads to higher all adverse events compared with placebo/observation (moderate certainty).
1 finding from 1 review